CAMLINFINENSECamlin Fine Sciences LimitedHighNeutral
Announced Tue, 17 Mar · 24:20 IST

Camlin Fine Sciences Limited has informed the Exchange about press release issued by the Company.

Listed Co AcquisitionOpen Offer TriggeredStrategic Transactions View source PDF

CAMLINFINE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.8%1-day move
₹131.93
prior close
₹132.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1+0.0-0.3-0.1-1.8-9.4-9.6-15.9-13.6-20.7-21.0-19.5-7.5+6.2
Up moveDown movePending
AI summary

Camlin Fine Sciences (CFSL) already acquired a 78.68% stake in French listed company Vinpai in November 2025 at €3.60 per share, and now holds 83.82% of share capital after converting its bonds. CFSL is filing a mandatory cash tender offer (OPAS) for the remaining Vinpai shares at the same price of €3.60, but the draft filing has been pushed back from end-February 2026 to early May 2026, citing Indian forex regulatory constraints and the need to include Vinpai's 2025 annual results (due April 16, 2026). Importantly, CFSL has decided not to do a squeeze-out, so Vinpai will stay listed on Euronext Growth Paris. CFSL is also exploring a European group restructuring to create synergies across its European subsidiaries.

Likely market impact

The delay in the tender offer timeline introduces some uncertainty, but the price remains unchanged at €3.60 per share. Deciding not to delist Vinpai preserves CFSL's optionality and access to European capital markets for future growth, while a group restructuring could unlock synergies that benefit shareholders over time.